Method for the production of transgenic proteins useful in the treatment of obesity and diabetes

• US 20050186608A1
• Filed: 02/17/2005
• Published: 08/25/2005
• Est. Priority Date: 02/19/2004
• Status: Abandoned Application

• Current Assignee: GTC Biotherapeutics, Inc.
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Olsen, Byron V.
• Application Number:
  US11/060,291
• Publication Number:
  US 20050186608A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical

Abstract

Transgenic proteins therapeutically useful in the treatment of obesity and related conditions can be produced in and purified from the milk of transgenic animals. The peptides are made as transgenic proteins with a suitable transgenic partner such as human recombinant protein of interest.

Claims

1. A transgenically produced recombinant protein, encoded by a transgene DNA construct comprising a polypeptide domain which has a desired bioactivity comprising said transgenic protein or fragment thereof wherein said polypeptide domain retains its endogenous physiological activity and is useful in reducing the body-weight of a mammal.

2. The transgenic protein of claim 1, wherein said transgenic protein is the product of a contiguous coding sequence of DNA.

3. The transgenically produced protein of claim 1, wherein said protein is selected from the group comprising:

a) Leptin;

b) Glucagon;

c) Subpeptide PYY; and

,

d) α

-MSH.

4. A method of treating obesity or other disease condition medically related to obesity comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.

5. A method as recited in claim 4 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day.

6. A recombinant protein as recited in claim 1 wherein the mammal is a human.

7. A recombinant DNA vector comprising the nucleic acid sequence of the transgenic protein of claim 1.

8. A host cell transformed with said recombinant DNA vector of claim 7.

9. A recombinant DNA vector comprising the nucleic acid sequence of the recombinant transgenic protein of claim 1 wherein said vector is an expression vector comprising a promoter operably linked to a transgenic protein of claim 1.

10. The method of claim 1 wherein said DNA construct encoding a desired transgenic protein is actuated by at least one beta-casein promoter.

11. A recombinant transgenic protein produced by a method comprising:

(a) expressing the transgenic protein of claim 1 by a mammary epithelial cell; and

(b) recovering the protein.

12. The recombinant transgenic protein of claim 11, wherein said transgenic protein further comprises an N-terminal methionine.

13. The method of claim 4 wherein said disease condition is Diabetes Mellitus.

14. The method of claim 4 wherein said disease condition is Hypertension.

15. The method of claim 4 wherein said disease condition is Atheriosclerosis.

16. The method of claim 4 wherein said disease condition is Insulin Resistance.

17. The method of claim 13 wherein said disease condition is Diabetes Mellitus and treatment of said disease condition further comprises treatment with an effective amount of a second composition said second composition being selected from the group consisting of:

insulin, insulin lente, and thiazolidinediones.

18. The recombinant protein of claim 1, wherein said transgenic protein is expressed by a prokaryotic cell.

19. The transgenic protein of claim 1, wherein said transgenic protein is expressed by a eukaryotic cell in in vitro cell culture conditions.

20. The transgenic protein of claim 19, wherein said transgenic protein is expressed by an animal cell.

21. The transgenic protein of claim 20, wherein said animal cell is a CHO cell.

22. The transgenic protein of claim 20, wherein said animal cell is a COS cell.

23. The transgenic protein of claim 19, wherein said transgenic protein is expressed by a yeast.

24. The transgenic protein of claim 23, wherein said yeast is Saccharomyces.

25. A method for the production of transgenic animals capable of producing a transgenic protein of interest comprising:

transfecting a non-human mammalian cell-line with a transgene DNA construct encoding a desired transgenic protein;

selecting a cell line(s) in which said transgene DNA construct has been inserted into the genome of that cell or cell-line; and

performing a first nuclear transfer procedure to generate a first transgenic animal heterzygous for the desired gene said animal being capable of expressing said transgenic protein of interest in its milk.

26. The method of claim 25 further comprising:

characterizing the genetic composition of said first heterzygous transgenic animal;

selecting cells homozygous for said desired transgene DNA construct through the use of a selective agent;

characterizing surviving cells using known molecular biolology methods; and

picking surviving cells or cell colonies cells for use in a second round of nuclear transfer or embryo transfer; and

producing a second transgenic animal homozygous for said desired transgene DNA construct.

27. The method of claim 25 wherein said transgene DNA construct is operatively linked to a mammary tissue-specific promoter which enables the obesity related transgenic protein product of said transgene DNA construct to be produced in the milk of a transgenic non-human mammal.

28. The transgenic mammal of claim 27, wherein said promoter is the beta-casein promoter.

29. The resultant milk derived from the offspring of the methods of claim 28.

30. A method for treating a human disease or pathologic condition related to or caused by obesity with a composition of matter containing a recombinant transgenic protein, said transgenic protein encoding a human recombinant protein selected from the group consisting of:

Leptin;

Glucagon;

subpeptide PYY;

α

-MSH;

a dysfunctional Ghrelin Receptor;

a dysfunctional MC-1 Receptor;

a dysfunctional NPY Y1 Receptor;

a dysfunctional NPY Y5 Receptor;

a dysfunctional GAL1 Receptor;

a dysfunctional GAL2 Receptor;

a dysfunctional GAL3 Receptor;

a dysfunctional Orexin Receptor 1; and

a dysfunctional Orexin Receptor 2.

31. The method of claim 30 wherein said human disease is further comprised of the following disease conditions:

diabetes mellitus;

insulin resistance;

leptin resistance;

hypertension;

atheriosclerosis;

impaired glucose tolerance; and

hyperphagia.

32. The method of claim 31 wherein said human disease condition is diabetes and said method of treatment includes administering a therapeutically effective amount of a recombinant protein of interest in addition to insulin via pump means.

40. A method as recited in claim 30 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day of each recombinant protein.

33. A method for treating a human disease related to undesirably low body weight or weight loss with a composition of matter containing a recombinant transgenic protein, said transgenic protein encoding a human recombinant protein selected from the group consisting of:

a dysfunctional Leptin receptor;

Ghrelin;

a dysfunctional glucagons Receptor;

Agouti Signalling Protein;

a dysfunctional MC-4 Receptor;

NPY;

Agouti Related Protein (AGRP);

a dysfunctional MC-3 Receptor;

Galanin;

an Orexin A polypeptide; and

an Orexin B polypeptide.

34. The method of claim 33 wherein said human disease is further comprised of the following disease conditions:

anorexia nervosa;

wasting disease;

AIDS wasting; and

Prader-Willi Syndrome.

41. A method as recited in claim 33 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day of each recombinant protein.

35. A method for treating a human disease or pathologic condition related to or caused by obesity with two proteins, wherein a first protein is recombinant leptin and a second protein is a composition of matter containing a recombinant transgenic protein, said second protein is a human recombinant protein selected from the group consisting of:

Glucagon;

subpeptide PYY;

α

-MSH;

a dysfunctional Ghrelin Receptor;

a dysfunctional MC-1 Receptor;

a dysfunctional NPY Y1 Receptor;

a dysfunctional NPY Y5 Receptor;

a dysfunctional GAL1 Receptor;

a dysfunctional GAL2 Receptor;

a dysfunctional GAL3 Receptor;

a dysfunctional Orexin Receptor 1; and

a dysfunctional Orexin Receptor 2.

36. The method of claim 35 wherein said human disease is further comprised of the following disease conditions:

diabetes mellitus;

insulin resistance;

leptin resistance;

hypertension;

atheriosclerosis;

impaired glucose tolerance; and

hyperphagia.

37. The method of claim 36 wherein said human disease condition is diabetes and said method of treatment includes administering a therapeutically effective amount of recombinant proteins of interest in addition to insulin via pump means.

42. A method as recited in claim 35 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day of each recombinant protein.

38. A method for treating a human disease related to undesirably low body weight or weight loss with two recombinant proteins, wherein a first protein is recombinant ghrelin and a second protein is a human recombinant protein selected from the group consisting of:

a dysfunctional Leptin receptor;

a dysfunctional glucagons Receptor;

Agouti Signalling Protein;

a dysfunctional MC-4 Receptor;

NPY;

Agouti Related Protein (AGRP);

a dysfunctional MC-3 Receptor;

Galanin;

an Orexin A polypeptide; and

an Orexin B polypeptide.

39. The method of claim 38 wherein said human disease is further comprised of the following disease conditions:

anorexia nervosa;

wasting disease;

AIDS wasting; and

Prader-Willi Syndrome.

43. A method as recited in claim 38 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day of each recombinant protein.